Sex Hormone Levels in the Serum of Patients with Pancreatic Adenocarcinoma

I. Fyssas; K. N. Syrigos; M. M. Konstandoulakis; S. Papadopoulos; N. Milingos; M. Anapliotou; J. Waxman; B. C. Golematis

doi:10.1055/s-2007-979002

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 1997; 29(3): 115-118
DOI: 10.1055/s-2007-979002

Originals Clinical

Sex Hormone Levels in the Serum of Patients with Pancreatic Adenocarcinoma

I. Fyssas¹ , K. N. Syrigos¹ ^, ² , M. M. Konstandoulakis¹ , S. Papadopoulos¹ , N. Milingos¹ , M. Anapliotou³ , J. Waxman² , B. C. Golematis¹

¹1st Department of Propaedeutic Surgery, Hippokration Hospital, Athens Medical School, Athens, Greece
²Department of Clinical Oncology, Hammersmith Hospital, Royal Postgraduate Medical School, London, United Kingdom
³Endocrine Unit, Department of Pathophysiology, Laikon Hospital, Athens Medical School, Athens, Greece

Abstract

als PDF herunterladen

The objective of this study was to evaluate the levels of several pituitary and gonadal hormones in pancreatic adenocarcinoma. We examined circulating levels of LH, FSH, Testosterone, Oestradiol, Progesterone and Δ4-Androstenedione in 36 patients with pancreatic adenocarcinoma, 12 patients with chronic pancreatitis and 87 age matched controls. According to our findings males with pancreatic cancer were found to have higher levels of FSH (p < 0.01), LH and oestradiol (p < 0.001) and lower levels of progesterone (p < 0.01) and testosterone (p < 0.05) than the controls. Female patients with pancreatic cancer were found to have higher levels of oestradiol (p < 0.001) and lower levels of LH, FSH and progesterone (p < 0.001), compared with group of healthy volunteers. Our data provide evidence of a generalised dysfunction of the hypothalamic-hypophysial-gonadal axis in pancreatic cancer patients.

Key words

Luteinising Hormone - Follicule Stimulating Hormone - Oestradiol - Progesterone - Testosterone - D4-Androstenedione - Pancreatic Cancer

PDF (331 kb)